CRBU vs EDIT
CRBU: Caribou develops off-the-shelf CRISPR-engineered CAR-T cell therapies designed to make cellular immunotherapy faster, cheaper, and accessible to more blood cancer patients. EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation.
Side-by-side fundamentals
| Metric | CRBU | EDIT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.66 | $2.78 | |
| Market cap as of 2026-07-23 | $165M | $421M | |
| Net margin as of 2026-07-23 | -1189.1% | -281.6% | EDIT higher |
| Operating margin as of 2026-07-23 | -1257.4% | -281.3% | EDIT higher |
| ROE as of 2026-07-23 | -100.1% | -677.4% | CRBU higher |
| ROA as of 2026-07-23 | -72.0% | -58.3% | EDIT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 12.40 | CRBU lower |
| Revenue growth (YoY) as of 2026-07-23 | +13.0% | +8.0% | CRBU higher |
| Revenue CAGR (3y) SEC XBRL | -7.0% | +27.1% | EDIT higher |
| Beta as of 2026-07-23 | 2.33 | 2.08 | |
| 1-year return as of 2026-07-22 close | -20.3% | -8.3% | EDIT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.